GlassScriptPhysician profile
Amitabha Sarma
NPI 1811965874
$4,584.64
in general payments reported to CMS, 2019-2025
43 companies · $617 in 2025
The $617 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $24.49 · 2021: $105 · 2022: $282 · 2023: $1,556 · 2024: $1,809 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,863.28 |
| Education | $118.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $663.20 | 2019-2025 | |
| Janssen Biotech, INC. | $596.73 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Alexion Pharmaceuticals, INC. | $407.54 | 2023-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $348.84 | 2023-2025 | Calquence, Onglyza |
| Merck Sharp & Dohme LLC | $273.97 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $260.20 | 2019-2025 | Enhertu, Injectafer |
| Pfizer INC. | $213.86 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $170.74 | 2023-2024 | Myrisk, Precisetumor |
| Genentech USA, INC. | $144.93 | 2023-2025 | Venclexta, Tecentriq, Gazyva |
| Astellas Pharma US INC | $136.64 | 2019-2025 | Padcev, Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $115.98 | 2023 | Imbruvica, Epkinly |
| Eisai INC. | $85.37 | 2022-2024 | |
| Genzyme Corporation | $84.37 | 2024 | |
| Amgen INC. | $79.11 | 2022-2023 | Blincyto, Kyprolis, Lumakras |
| Incyte Corporation | $73.82 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitabha Sarma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.